A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer

  • Gurney, Howard (Primary Chief Investigator)
  • Cunningham, Jacob (Research Assistant)
  • Butala, Radhika (Research Assistant)

Project: Other

Project Details

Short titleNIAGARA
Effective start/end date10/10/186/10/23